Table 1.
Baseline Patient Characteristics
| Characteristic | Benign |
Resectable |
Resected |
Locally Advanced |
Metastatic |
P | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | No. | % | ||
| No. of patients | 12 | 15.5 | 13 | 17 | 13 | 17 | 27 | 35 | 12 | 15.5 | |
| Age, years | .182 | ||||||||||
| Mean | 61.1 | 67.3 | 63.3 | 68.7 | 64.0 | ||||||
| SD | 12.7 | 9.1 | 8.3 | 10.2 | 9.2 | ||||||
| Male sex | 5 | 41.7 | 4 | 30.8 | 8 | 61.5 | 15 | 55.6 | 6 | 5.0 | .514 |
| Tumor size, cm* | .045 | ||||||||||
| Mean | 2.3 | 2.6 | 2.5 | 3.7 | 3.2 | ||||||
| SD | 1.4 | 1.4 | 0.0 | 1.3 | 1.5 | ||||||
| CA 19-9 , U/mL† | .072 | ||||||||||
| Mean | 23.4 | 426.8 | 129.4 | 491.9 | 2,069.2 | ||||||
| SD | 18.8 | 724.3 | 256.5 | 818.6 | 4,130.0 | ||||||
| ECOG PS | .009 | ||||||||||
| Mean | 0.1 | 0.5 | 0.3 | 0.9 | 0.6 | ||||||
| SD | 0.3 | 0.7 | 0.5 | 0.8 | 0.5 | ||||||
| KPS, % | |||||||||||
| Mean | 98.3 | 92.3 | 96.2 | 85.6 | 92.5 | ||||||
| SD | 3.9 | 14.2 | 6.5 | 18.3 | 7.5 | .041 | |||||
Abbreviations: CA 19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperative Oncology Group performance status; KPS, Karnofsky performance status; SD, standard deviation.
*
Patients evaluable for tumor size: benign (n = 12), resectable (n = 12), locally advanced (n = 26), metastatic (n = 8), resected (n = 2).
†
CA 19-9: patients evaluable: benign (n = 7), resectable (n = 12), locally advanced (n = 26), metastatic (n = 9), resected (n = 10).